NVCT Matthew L. Kaplan bought Nuvectis Pharma, Inc. shares — SEC Form 4BUYNuvectis Pharma, Inc.

Matthew L. Kaplan, Director at Nuvectis Pharma, Inc. (NVCT), bought 11,000 shares at $5.84 ($64K) on 2025-11-05, disclosed to the SEC on 2025-11-06.

SEC EDGAR Filing

0001104659-25-107418

View on SEC EDGAR

Why this matters (generating…)

High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.

Modest57/100

Nothing distinguishes this filing.

First-Time BuyerUnusually Large TradeOpportunistic Buy

Trade Context

•Increased holdings by 10%
•3 other insiders also purchased in last 30 days
•Stock down -37% in previous 6 months
•Micro-Cap (Under $300M market cap — highest insider signal alpha)

Filing Info

Filed2025-11-06

Traded2025-11-05

Accession0001104659-25-107418

SourceSEC EDGAR (Historical)

Insider

NameMatthew L. Kaplan

TitleDirector

PIT GradeInsiderC

Score—

View Company View Insider

Related Trades by This Insider

Ticker	Type	Filed	Value	7d Stock	Filing
NVCT	BUY	2022-05-16	$51K	—	Filing →

Get an email when an insider at NVCT files

Free account. Follow NVCT and up to 10 more companies.

Follow NVCT for free

NVCT Matthew L. Kaplan bought Nuvectis Pharma, Inc. shares — SEC Form 4BUYNuvectis Pharma, Inc.

Trade Context

Filing Info

Insider

Related Trades by This Insider

Trade Details

Outcomes